美国 · SEC FORM 4
AVITA Medical, Inc.
RCEL · Nasdaq; OTC · CIK 0001762303 · Healthcare · Medical Devices
内部人信号
2 位买方 · 12 条买入交易行 · $213.5K 买入总额
为什么有这个信号?
评分构成
每条进度条表示其对当前分数的贡献;权重和公式保持不变。
哪些因素限制了当前分数?
- ⚠ Cluster breadth is moderate · 2 insider(s), not 4+
- ⚠ Purchase size is modest relative to the model scale
- ⚠ Purchase activity is becoming less recent
- ✓ 角色得分高 · 买入者中职位最高的是:CFO
Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.
US-v1.2 按当前 180 天规则给合资格的股票买入打分。分数只表示研究的先后,不是收益预测或概率。回测没有显示美国分数越高、之后的表现越好。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型;卖出仅作为背景。
—
买方广度与集中度
Roles in the peak window: CFO, Director. Concentration uses priced qualifying P lines only and does not change the saved score.
信号历史
最新留档分数
- 51.0
- 51.0
- 50.9
- 50.9
- 50.8
Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
市场背景补充近期价格表现与风险信息,不影响内部人信号。
价格表现
- 1M
- +34.0%
- 3M
- +234.4%
- 6M
- +163.7%
- 12M
- +139.7%
波动率与流动性
- 波动率
- 96.9%
- Beta
- —
- 平均每日成交额
- USD 5.9M
估值
- 市值
- USD 408.5M
- P/E
- —
基本面
- 利润率
- -67.8%
- ROE
- —
- 细分行业
- Medical Devices
市场数据
价格数据截至:2026-10-11 · 价格来源:OpenBB/yfinance; 成交量来自 本机价格缓存 (yfinance) · 来自 SEC 申报文件:市值, 利润率 · 财年截止日:2025-12-31 · 市值 = 申报文件封面所列的已发行股数 × 最新收盘价。股数日期:2026-08-03 · Status: PASS
空头余额
空头余额是券商向 FINRA 申报的外部背景数据,不影响内部人信号。
- 空头股数
- 2,887,981
- 上期报告
- 2,885,693
- 日均成交量
- 313,878
- 回补天数
- 9.2
FINRA 结算日:2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数,每月两个结算日之后约一周公布;不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-06-12 | O'Toole David D | 买入 (P) | Common Stock | 2,000 | USD 3.97 | USD 7,940 | SEC 申报 ↗ |
| 2026-06-09 | Woody Joseph Fralin | 买入 (P) | Common Stock | 5,200 | USD 4.00 | USD 20,800 | SEC 申报 ↗ |
| 2026-06-09 | Woody Joseph Fralin | 买入 (P) | Common Stock | 10,000 | USD 4.19 | USD 41,900 | SEC 申报 ↗ |
| 2026-06-03 | Woody Joseph Fralin | 买入 (P) | Common Stock | 10,000 | USD 4.09 | USD 40,950 | SEC 申报 ↗ |
| 2026-06-02 | Woody Joseph Fralin | 买入 (P) | Common Stock | 10,000 | USD 4.20 | USD 41,950 | SEC 申报 ↗ |
| 2026-06-01 | Woody Joseph Fralin | 买入 (P) | Common Stock | 10,000 | USD 4.30 | USD 43,000 | SEC 申报 ↗ |
| 2026-05-20 | O'Toole David D | 买入 (P) | Common Stock | 2,000 | USD 4.26 | USD 8,520 | SEC 申报 ↗ |
| 2026-05-19 | O'Toole David D | 买入 (P) | Common Stock | 2,000 | USD 4.24 | USD 8,480 | SEC 申报 ↗ |
| 2026-03-11 | O'Toole David D | 买入 (P) | Common Stock | 1,800 | USD 4.78 | USD 8,604 | SEC 申报 ↗ |
| 2026-02-19 | O'Toole David D | 买入 (P) | Common Stock | 3,000 | USD 4.15 | USD 12,450 | SEC 申报 ↗ |
| 2025-08-28 | McNamara Robert | 买入 (P) | Common Stock | 10,000 | USD 4.50 | USD 45,000 | SEC 申报 ↗ |
| 2025-08-26 | O'Toole David D | 买入 (P) | Common Stock | 2,000 | USD 4.52 | USD 9,040 | SEC 申报 ↗ |
| 2025-08-19 | McNamara Robert | 买入 (P) | Common Stock | 10,000 | USD 5.00 | USD 50,000 | SEC 申报 ↗ |
| 2025-08-12 | O'Toole David D | 买入 (P) | Common Stock | 2,000 | USD 4.81 | USD 9,620 | SEC 申报 ↗ |
| 2025-03-06 | McNamara Robert | 买入 (P) | Common Stock | 11,000 | USD 8.30 | USD 91,300 | SEC 申报 ↗ |
Form 4 申报证据
19 transaction lines in the latest 365-day window; 127 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-06-12 | O'Toole David D | 买入 (P) | Common Stock | 2,000 | USD 3.97 | USD 7,940 | SEC 申报 ↗ |
| 2026-06-12 | O'Toole David D | 奖励/授予 (A) | Common Stock | 2,000 | USD 3.97 | USD 7,940 | SEC 申报 ↗ |
| 2026-06-09 | Woody Joseph Fralin | 买入 (P) | Common Stock | 5,200 | USD 4.00 | USD 20,800 | SEC 申报 ↗ |
展开近期 Form 4 证据 (15 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-06-12 | O'Toole David D | 买入 (P) | Common Stock | 2,000 | USD 3.97 | USD 7,940 | SEC 申报 ↗ |
| 2026-06-12 | O'Toole David D | 奖励/授予 (A) | Common Stock | 2,000 | USD 3.97 | USD 7,940 | SEC 申报 ↗ |
| 2026-06-09 | Woody Joseph Fralin | 买入 (P) | Common Stock | 5,200 | USD 4.00 | USD 20,800 | SEC 申报 ↗ |
| 2026-06-09 | Woody Joseph Fralin | 买入 (P) | Common Stock | 10,000 | USD 4.19 | USD 41,900 | SEC 申报 ↗ |
| 2026-06-03 | Woody Joseph Fralin | 买入 (P) | Common Stock | 10,000 | USD 4.09 | USD 40,950 | SEC 申报 ↗ |
| 2026-06-02 | Woody Joseph Fralin | 买入 (P) | Common Stock | 10,000 | USD 4.20 | USD 41,950 | SEC 申报 ↗ |
| 2026-06-01 | Woody Joseph Fralin | 买入 (P) | Common Stock | 10,000 | USD 4.30 | USD 43,000 | SEC 申报 ↗ |
| 2026-05-29 | Vance Cary Guy | 奖励/授予 (A) | Common Stock | 5,000 | USD 3.05 | USD 15,250 | SEC 申报 ↗ |
| 2026-05-29 | O'Toole David D | 奖励/授予 (A) | Common Stock | 5,000 | USD 3.05 | USD 15,250 | SEC 申报 ↗ |
| 2026-05-20 | O'Toole David D | 买入 (P) | Common Stock | 2,000 | USD 4.26 | USD 8,520 | SEC 申报 ↗ |
| 2026-05-19 | O'Toole David D | 买入 (P) | Common Stock | 2,000 | USD 4.24 | USD 8,480 | SEC 申报 ↗ |
| 2026-03-11 | O'Toole David D | 买入 (P) | Common Stock | 1,800 | USD 4.78 | USD 8,604 | SEC 申报 ↗ |
| 2026-02-19 | O'Toole David D | 买入 (P) | Common Stock | 3,000 | USD 4.15 | USD 12,450 | SEC 申报 ↗ |
| 2026-02-18 | O'Toole David D | 奖励/授予 (A) | Common Stock | 105,470 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-18 | KELSEY NICOLE | 奖励/授予 (A) | Common Stock | 98,390 | USD — | USD — | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | RCEL |
| CIK | 0001762303 |
| 行业 | Healthcare |
| 细分行业 | Medical Devices Yahoo Finance |
| SEC SIC | 3841 Surgical & Medical Instruments & Apparatus |
| 交易所 | Nasdaq; OTC |
数据覆盖
| 本地 Form 4 历史 | 127 transaction lines from 2020-07-16 to 2026-06-12 48 P purchase lines · 13 S sale lines · 66 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.